Newly diagnosed diabetes at COVID-19 admission profiled
Mar 02, 2022
Lower levels of glucose and HbA1c, and higher levels of inflammatory markers, were seen in COVID-19 patients with newly diagnosed diabetes mellitus versus preexisting diabetes.
Monoclonal antibody therapy may cut COVID-19 hospitalizations
Aug 31, 2021
Lower hospitalization rates were seen at 14, 21 and 28 days for high-risk patients with mild-to-moderate COVID-19 who received casirivimab-imdevimab.
Long-term glycemic control cuts risk for severe COVID-19 with type 2 diabetes mellitus
Dec 07, 2021
Additionally, the use of corticosteroids or a combo of metformin and insulin significantly cut intensive care risk.